<DOC>
	<DOCNO>NCT01225172</DOCNO>
	<brief_summary>The purpose study evaluate oral dos BMS-754807 combination letrozole BMS-754807 alone safe efficacious locally advanced metastatic hormone receptor positive breast cancer subject progress prior non-steroidal aromatase inhibitor treatment .</brief_summary>
	<brief_title>Study BMS-754807 Combined With Letrozole BMS-754807 Alone Patients With Hormone Receptor-Positive Breast Cancer Resistance Non-Steroidal Aromatase Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Postmenopausal woman hormone receptorpositive HER2 negative breast cancer Disease progression follow nonsteroidal aromatase inhibitor treatment Known symptomatic brain metastasis Medical condition require chronic steroid History Type 1 2 Diabetes Uncontrolled significant cardiovascular ( CV ) disease Concomitant second malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>